Varian and Brainlab Combine TrueBeam STx with the Novalis
Radiosurgery Program
2 August 2010
Varian Medical Systems (Varian) and Brainlab are expanding
their radiosurgery partnership to incorporate their Novalis technology
and other Novalis radiosurgery program elements into the recently
launched TrueBeam STx system.
The expanded suite of products will be badged 'Novalis powered by
TrueBeam STx'. This will give clinicians radiosurgical and
image-guidance capabilities designed for targeted stereotactic
radiosurgery (SRS) and stereotactic body radiotherapy (SBRT)
treatments. It will include Brainlab iPlan treatment planning and
ExacTrac room-based X-ray imaging technology as well as Varian’s
HD120 MLC multileaf collimator for high resolution beam shaping.
“TrueBeam STx technology will significantly enhance the Varian-Brainlab
offering to the radiosurgery market with its significant speed and
precision,” said Dow Wilson, Executive Vice President, Oncology
Systems, Varian Medical Systems, Inc. “The Novalis Radiosurgery
Program includes a comprehensive package of clinical applications,
workflow, knowledgebase and training for radiosurgery.”
The TrueBeam STx is especially configured for advanced
radiosurgery and is designed to treat a moving target with
unprecedented speed and accuracy. A TrueBeam system can deliver
treatments up to 50 percent faster and with a dose delivery rate of
up to 2400 monitor units per minute, double the maximum output of
earlier, industry-leading Varian systems. This makes it possible to
offer greater patient comfort by shortening treatments and to
improve precision by leaving less time for tumour motion during dose
delivery.
The agreement is an extension of a relationship between the two
companies that began in 1996, and grew with their collaboration on
the Novalis Tx radiosurgery platform, launched in 2007.
“Expanding our partnership with Varian to combine TrueBeam STx
with the Novalis Radiosurgery Program gives us a stronger and
broader platform for innovation in neurosurgery,” said Stefan
Vilsmeier, CEO, Brainlab. “We believe the combination of our leading
technologies can help make significant clinical advancements in the
fight against cancer and other neurological conditions. Our goal is
to increase access to advanced treatment,”